LPL Financial LLC Buys 15,267 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

LPL Financial LLC raised its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 39.0% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 54,402 shares of the company’s stock after purchasing an additional 15,267 shares during the period. LPL Financial LLC’s holdings in Cellebrite DI were worth $1,198,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. R Squared Ltd bought a new position in shares of Cellebrite DI in the fourth quarter worth about $100,000. Polen Capital Management LLC purchased a new stake in Cellebrite DI in the 4th quarter worth about $222,000. Victory Capital Management Inc. bought a new stake in shares of Cellebrite DI during the 4th quarter worth approximately $234,000. HighTower Advisors LLC bought a new stake in Cellebrite DI during the 4th quarter valued at about $274,000. Finally, Steward Partners Investment Advisory LLC raised its position in Cellebrite DI by 12.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company’s stock valued at $299,000 after purchasing an additional 1,463 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Stock Performance

Shares of CLBT opened at $18.90 on Friday. Cellebrite DI Ltd. has a one year low of $10.25 and a one year high of $26.30. The stock has a market cap of $4.53 billion, a P/E ratio of -13.60, a P/E/G ratio of 4.27 and a beta of 1.44. The stock has a 50-day moving average of $18.99 and a two-hundred day moving average of $20.08.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. Analysts predict that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on CLBT shares. JPMorgan Chase & Co. upped their price objective on Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Lake Street Capital increased their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of Cellebrite DI in a research note on Wednesday, April 2nd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $23.43.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.